Michael W Lawlor,Benedikt Schoser,Marta Margeta,Caroline A Sewry,Karra A Jones,Perry B Shieh,Nancy L Kuntz,Barbara K Smith,James J Dowling,Wolfgang Müller-Felber,Carsten G Bönnemann,Andreea M Seferian,Astrid Blaschek,Sarah Neuhaus,A Reghan Foley,Dimah N Saade,Etsuko Tsuchiya,Ummulwara R Qasim,Margaret Beatka,Mariah J Prom,Emily Ott,Susan Danielson,Paul Krakau,Suresh N Kumar,Hui Meng,Mark Vanden Avond,Clive Wells,Heather Gordish-Dressman,Alan H Beggs,Sarah Christensen,Edward Conner,Emma S James,Jun Lee,Chanchal Sadhu,Weston Miller,Bryan Sepulveda,Fatbardha Varfaj,Suyash Prasad,Salvador Rico

Abstract:Background: X-linked myotubular myopathy (XLMTM) is a rare, life-threatening congenital muscle disease caused by mutations in the MTM1 gene that result in profound muscle weakness, significant respiratory insufficiency, and high infant mortality. There is no approved disease-modifying therapy for XLMTM. Resamirigene bilparvovec (AT132; rAAV8-Des-hMTM1) is an investigational adeno-associated virus (AAV8)-mediated gene replacement therapy designed to deliver MTM1 to skeletal muscle cells and achieve long-term correction of XLMTM-related muscle pathology. The clinical trial ASPIRO (NCT03199469) investigating resamirigene bilparvovec in XLMTM is currently paused while the risk:benefit balance associated with this gene therapy is further investigated. Methods: Muscle biopsies were taken before treatment and 24 and 48 weeks after treatment from ten boys with XLMTM in a clinical trial of resamirigene bilparvovec (ASPIRO; NCT03199469). Comprehensive histopathological analysis was performed. Findings: Baseline biopsies uniformly showed findings characteristic of XLMTM, including small myofibres, increased internal or central nucleation, and central aggregates of organelles. Biopsies taken at 24 weeks post-treatment showed marked improvement of organelle localisation, without apparent increases in myofibre size in most participants. Biopsies taken at 48 weeks, however, did show statistically significant increases in myofibre size in all nine biopsies evaluated at this timepoint. Histopathological endpoints that did not demonstrate statistically significant changes with treatment included the degree of internal/central nucleation, numbers of triad structures, fibre type distributions, and numbers of satellite cells. Limited (predominantly mild) treatment-associated inflammatory changes were seen in biopsy specimens from five participants. Interpretation: Muscle biopsies from individuals with XLMTM treated with resamirigene bilparvovec display statistically significant improvement in organelle localisation and myofibre size during a period of substantial improvements in muscle strength and respiratory function. This study identifies valuable histological endpoints for tracking treatment-related gains with resamirigene bilparvovec, as well as endpoints that did not show strong correlation with clinical improvement in this human study. Funding: Astellas Gene Therapies (formerly Audentes Therapeutics, Inc.).

Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function

Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility

Identification of human metabolites of fast skeletal troponin activators Tirasemtiv and Reldesemtiv for doping control purposes

A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis

The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy

Small molecule-mediated refolding and activation of myosin motor function

Development of a high-throughput screen to identify small molecule enhancers of sarcospan for the treatment of Duchenne muscular dystrophy

Cardiac Troponin Activator CK-963 Increases Cardiac Contractility in Rats

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy

Effects of gene replacement therapy with resamirigene bilparvovec (AT132) on skeletal muscle pathology in X-linked myotubular myopathy: results from a substudy of the ASPIRO open-label clinical trial

Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic Potential

SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF A CLC-1 INHIBITOR - A FIRST-IN-CLASS COMPOUND THAT ENHANCES MUSCLE EXCITABILITY: A PHASE I, SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY

Identification of bazedoxifene for the treatment of LGMD R2 by high throughput screening

Leveraging Quantitative Systems Pharmacology Approach into Development of Human Recombinant Follistatin Fusion Protein for Duchenne Muscular Dystrophy

Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy

Drug discovery for heart failure targeting myosin-binding protein C

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial

Structure-activity Relationship (SAR) Studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) As NF-ҡB Activators for the Treatment of ALS

Drug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology

Therapeutics Targeting Skeletal Muscle in Amyotrophic Lateral Sclerosis